- Home
- XXII vs BIAF Comparison
XXII vs BIAF Comparison
Compare XXII & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XXII | BIAF |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | XXII | BIAF |
|---|---|---|
| Price | $1.04 | $1.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 190.3K | 105.9K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,346,000.00 | $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $136.46 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $0.78 | $1.25 |
| 52 Week High | $294.98 | $46.53 |
Technical Indicators
Market Signals| Indicator | XXII | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 44.37 |
| Support Level | $0.98 | $1.34 |
| Resistance Level | $1.09 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 83.36 | 66.08 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.